Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease-Reference-Cited by-同舟云学术

Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease

Published:2017-06 Issue:3 Volume:19 Page:211-217
ISSN:1760-2734
Container-title:Journal of Veterinary Cardiology
language:en
Short-container-title:Journal of Veterinary Cardiology

Author:

Oyama M.A.,Solter P.F.,Thorn C.L.,Stern J.A.

Publisher

Elsevier BV

Subject

General Veterinary,Physiology

Reference21 articles.

1. Neuroendocrine evaluation of cardiac disease;Sisson;Vet Clin North Am Small Anim Pract,2004

2. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited;Goetze;Clin Chem,2004

3. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency;Takemura;J Vet Med Sci,2009

4. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases;Chang;Nature,1989

5. Possible mechanisms for brain natriuretic peptide resistance in heart failure with a focus on interspecies differences and canine BNP biology;Baerts;Vet J,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-type natriuretic peptide is upregulated by c-Jun N-terminal kinase and contributes to septic hypotension;JCI Insight;2020-04-23

2. Left ventricular myocardial remodeling in dogs with mitral valve endocardiosis;April-2020;2020

3. Cardiovascular Pharmacotherapeutics;Pharmacotherapeutics for Veterinary Dispensing;2019-02-15

4. Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease;Journal of Veterinary Internal Medicine;2019-01-31